Author:
Lortholary A.,Largillier R.,Weber B.,Gladieff L.,Alexandre J.,Durando X.,Slama B.,Dauba J.,Paraiso D.,Pujade-Lauraine E.
Reference37 articles.
1. Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): a GINECO study;Pujade-Lauraine;Proc Am Soc Clin Oncol,2002
2. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer;Cree;Anticancer Drugs,2007
3. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer;Bolis;Gynecol Oncol,1999
4. Oxaliplatin or paclitaxel;Piccart;J Clin Oncol in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group,2000
5. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study;Thigpen;J Clin Oncol,1994
Cited by
74 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献